Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 (sacubitril/valsartan) vs enalapril in Japanese patients with chronic heart failure with reduced ejection fraction
jRCT2080222891Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2080222891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222891.